Quinagolide (BioDeep_00000547428)
代谢物信息卡片
Quinagolide
化学式: C20H33N3O3S (395.22425080000005)
中文名称: 喹高利特
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCN1CC(CC2C1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC
InChI: InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1
描述信息
G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CB - Prolactine inhibitors
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
同义名列表
1 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:135627
- KEGGdrug: D07217
- PubChem: 3086401
- Metlin: METLIN2207
- DrugBank: DB09097
- ChEMBL: CHEMBL290962
- CAS: 140630-80-4
- CAS: 87056-78-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- N Vanacker, S Ollier, F Beaudoin, R Blouin, P Lacasse. Effect of inhibiting the lactogenic signal at calving on milk production and metabolic and immune perturbations in dairy cows.
Journal of dairy science.
2017 Jul; 100(7):5782-5791. doi:
10.3168/jds.2017-12570. [PMID: 28501406] - S Ollier, F Beaudoin, N Vanacker, P Lacasse. Effect of reducing milk production using a prolactin-release inhibitor or a glucocorticoid on metabolism and immune functions in cows subjected to acute nutritional stress.
Journal of dairy science.
2016 Dec; 99(12):9949-9961. doi:
10.3168/jds.2016-11711. [PMID: 27743662] - S Ollier, X Zhao, P Lacasse. Effects of feed restriction and prolactin-release inhibition at drying off on metabolism and mammary gland involution in cows.
Journal of dairy science.
2014; 97(8):4942-54. doi:
10.3168/jds.2014-7914. [PMID: 24881791] - S Ollier, X Zhao, P Lacasse. Effect of prolactin-release inhibition on milk production and mammary gland involution at drying-off in cows.
Journal of dairy science.
2013 Jan; 96(1):335-43. doi:
10.3168/jds.2012-5955. [PMID: 23164222] - Peter Cackett, Graeme Eunson, Louise Bath, Alan Mulvihill. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Future oncology (London, England).
2012 Dec; 8(12):1621-6. doi:
10.2217/fon.12.149. [PMID: 23231524] - Rosalie Broekhof, Manon J Gosselink, Hanno Pijl, Erik J Giltay. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
General hospital psychiatry.
2012 Mar; 34(2):209.e1-3. doi:
10.1016/j.genhosppsych.2011.07.004. [PMID: 21872335] - Robert Krysiak, Agnieszka Kędzia, Bogusław Okopień. Unfavorable effects of hyperprolactinemia in autoimmune endocrine disorders.
Neuro endocrinology letters.
2012; 33(3):298-300. doi:
NULL. [PMID: 22635088] - P Lacasse, V Lollivier, R M Bruckmaier, Y R Boisclair, G F Wagner, M Boutinaud. Effect of the prolactin-release inhibitor quinagolide on lactating dairy cows.
Journal of dairy science.
2011 Mar; 94(3):1302-9. doi:
10.3168/jds.2010-3649. [PMID: 21338795] - Gergely Lakatos, Nikolette Szücs, Zoltán Kender, Sándor Czirják, Károly Rácz. [Macroprolactinemia associated with pituitary macroadenoma: treatment with quinagolide].
Orvosi hetilap.
2010 Jun; 151(26):1072-5. doi:
10.1556/oh.2010.28896. [PMID: 20558354] - M Sarkar, B K Dutta Borah, B S Prakash. Efficacy of Ovsynch protocol with antiprolactin treatment for timed artificial insemination during non-breeding seasons in yaks (Poephagus grunniens L.).
Reproduction in domestic animals = Zuchthygiene.
2010 Jun; 45(3):393-8. doi:
10.1111/j.1439-0531.2008.01196.x. [PMID: 19735436] - K S Roy, B S Prakash. Plasma progesterone, oestradiol-17β and total oestrogen profiles in relation to oestrous behaviour during induced ovulation in Murrah buffalo heifers.
Journal of animal physiology and animal nutrition.
2009 Aug; 93(4):486-95. doi:
10.1111/j.1439-0396.2008.00830.x. [PMID: 18507697] - K S Roy, B S Prakash. Changes in endocrine profiles during ovsynch and ovsynch plus norprolac treatment in Murrah buffalo heifers at hot summer season.
Tropical animal health and production.
2009 Apr; 41(4):677-87. doi:
10.1007/s11250-008-9241-3. [PMID: 18932011] - Antoni Hrycek, Grazyna Pochopień-Kenig, Joanna Scieszka. Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide.
Autoimmunity.
2007 May; 40(3):217-22. doi:
10.1080/08916930701306817. [PMID: 17453721] - K S Roy, B S Prakash. Development and validation of a simple, sensitive enzyme immunoassay (EIA) for quantification of prolactin in buffalo plasma.
Theriogenology.
2007 Feb; 67(3):572-9. doi:
10.1016/j.theriogenology.2006.08.018. [PMID: 17049591] - Anne Barlier, Philippe Jaquet. Quinagolide--a valuable treatment option for hyperprolactinaemia.
European journal of endocrinology.
2006 Feb; 154(2):187-95. doi:
10.1530/eje.1.02075. [PMID: 16452531] - Miklós Góth, Erika Hubina, László Kovács, István Szabolcs. [Novel pharmacologic therapies in acromegaly].
Orvosi hetilap.
2002 May; 143(19 Suppl):1057-62. doi:
NULL. [PMID: 12063860] - A Saveanu, I Morange-Ramos, G Gunz, H Dufour, A Enjalbert, P Jaquet. A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies.
European journal of endocrinology.
2001 Jul; 145(1):35-41. doi:
10.1530/eje.0.1450035. [PMID: 11415850] - A Hrycek, P Cieślik, J Tustanowski, S Nowak, P Jedynak. Selected serum cytokines in systemic lupus erythematosus treated with quinagolide.
Lupus.
2001; 10(6):424-30. doi:
10.1191/096120301678646173. [PMID: 11434578] - P N Schultz, L Ginsberg, I E McCutcheon, N Samaan, M Leavens, R F Gagel. Quinagolide in the management of prolactinoma.
Pituitary.
2000 Dec; 3(4):239-49. doi:
10.1023/a:1012884214668. [PMID: 11788012] - V Rohmer, E Freneau, I Morange, C Simonetta. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Annales d'endocrinologie.
2000 Nov; 61(5):411-7. doi:
NULL. [PMID: 11084391] - F R Nobels, W W de Herder, W M van den Brink, D J Kwekkeboom, L J Hofland, J Zuyderwijk, F H de Jong, S W Lamberts. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma.
European journal of endocrinology.
2000 Nov; 143(5):615-21. doi:
10.1530/eje.0.1430615. [PMID: 11078985] - S Koloszár, A Keresztúri, L Kovács. [Treatment of hyperprolactinemic anovulation with the dopamin-agonist quinagolide].
Orvosi hetilap.
2000 Jul; 141(29):1621-3. doi:
NULL. [PMID: 10962898] - D A De Luis, A Becerra, M Lahera, J I Botella, Valero, C Varela. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients.
Journal of endocrinological investigation.
2000 Jul; 23(7):428-34. doi:
10.1007/bf03343751. [PMID: 11005266] - A Di Sarno, M L Landi, P Marzullo, C Di Somma, R Pivonello, G Cerbone, G Lombardi, A Colao. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Clinical endocrinology.
2000 Jul; 53(1):53-60. doi:
10.1046/j.1365-2265.2000.01016.x. [PMID: 10931080] - A Colao, C Di Somma, S Loche, A Di Sarno, M Klain, R Pivonello, M Pietrosante, M Salvatore, G Lombardi. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Clinical endocrinology.
2000 Mar; 52(3):319-27. doi:
10.1046/j.1365-2265.2000.00902.x. [PMID: 10718830] - J Webster. Dopamine agonist therapy in hyperprolactinemia.
The Journal of reproductive medicine.
1999 Dec; 44(12 Suppl):1105-10. doi:
NULL. [PMID: 10649819] - P Marzullo, D Ferone, C Di Somma, R Pivonello, M Filippella, G Lombardi, A Colao. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
Pituitary.
1999; 1(2):115-20. doi:
10.1023/a:1009932521242. [PMID: 11081189] - L Ioannidou-Mouzaka, M Niagassas, A Galanos, A Kalovidouris. Pilot study on the treatment of cyclical mastodynia with Quinagolide.
European journal of gynaecological oncology.
1999; 20(2):117-21. doi:
NULL. [PMID: 10376428] - A Colao, S Loche, M Cappa, A Di Sarno, M L Landi, F Sarnacchiaro, G Facciolli, G Lombardi. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
The Journal of clinical endocrinology and metabolism.
1998 Aug; 83(8):2777-80. doi:
10.1210/jcem.83.8.5001. [PMID: 9709946] - C Di Somma, A Colao, A Di Sarno, M Klain, M L Landi, G Facciolli, R Pivonello, N Panza, M Salvatore, G Lombardi. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
The Journal of clinical endocrinology and metabolism.
1998 Mar; 83(3):807-13. doi:
10.1210/jcem.83.3.4674. [PMID: 9506732] - M Bontenbal, J A Foekens, S W Lamberts, F H de Jong, W L van Putten, H J Braun, J T Burghouts, G H van der Linden, J G Klijn. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
British journal of cancer.
1998; 77(1):115-22. doi:
10.1038/bjc.1998.18. [PMID: 9459155] - E Delgrange, J Crabbé, J Donckier. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
Hormone research.
1998; 49(5):250-3. doi:
10.1159/000023180. [PMID: 9568811] - D Ferone, S Lastoria, A Colao, P Varrella, G Cerbone, W Acampa, B Merola, M Salvatore, G Lombardi. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
The Journal of clinical endocrinology and metabolism.
1998 Jan; 83(1):248-52. doi:
10.1210/jcem.83.1.4493. [PMID: 9435450] - A Colao, D Ferone, P Marzullo, A Di Sarno, G Cerbone, F Sarnacchiaro, S Cirillo, B Merola, G Lombardi. Effect of different dopaminergic agents in the treatment of acromegaly.
The Journal of clinical endocrinology and metabolism.
1997 Feb; 82(2):518-23. doi:
10.1210/jcem.82.2.3648. [PMID: 9024247] - A Tabarin, B Catargi. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
Annales d'endocrinologie.
1997; 58(2):87-94. doi:
NULL. [PMID: 9239226] - W W de Herder, A E Reijs, D J Kwekkeboom, L J Hofland, F R Nobels, H Y Oei, E P Krenning, S W Lamberts. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
Clinical endocrinology.
1996 Dec; 45(6):755-67. doi:
10.1046/j.1365-2265.1996.8650876.x. [PMID: 9039343] - A Colao, M De Rosa, F Sarnacchiaro, A Di Sarno, M L Landi, E Iervolino, S Zarrilli, B Merola, G Lombardi. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males.
European journal of endocrinology.
1996 Nov; 135(5):548-52. doi:
10.1530/eje.0.1350548. [PMID: 8980156] - I Morange, A Barlier, I Pellegrini, T Brue, A Enjalbert, P Jaquet. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
European journal of endocrinology.
1996 Oct; 135(4):413-20. doi:
10.1530/eje.0.1350413. [PMID: 8921822] - C W Bodmer, S L Atkin, M W Savage, E A Masson, M C White. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
Clinical endocrinology.
1995 Jul; 43(1):49-53. doi:
10.1111/j.1365-2265.1995.tb01893.x. [PMID: 7641411] - A Colao, B Merola, F Sarnacchiaro, A Di Sarno, M L Landi, P Marzullo, G Cerbone, D Ferone, G Lombardi. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Hormone research.
1995; 44(5):222-8. doi:
10.1159/000184630. [PMID: 8582715] - J A Kremer, L A Schellekens, M F Segers, C M Thomas, R Rolland. Circulating inhibin levels in lactating and nonlactating women.
Fertility and sterility.
1994 Dec; 62(6):1150-6. doi:
10.1016/s0015-0282(16)57177-5. [PMID: 7957977] - B Merola, F Sarnacchiaro, A Colao, C Di Somma, A Di Sarno, D Ferone, A Selleri, M L Landi, G Schettini, C Nappi. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
1994 Sep; 8(3):175-81. doi:
10.3109/09513599409072452. [PMID: 7847102] - L Lévy, V Alvaro, C Dubray, D Joubert. Ca(2+)-dependent protein kinase C isoforms in rat pituitary hyperplasia: effect of in vivo treatment with quinagolide.
European journal of pharmacology.
1994 Aug; 268(3):327-34. doi:
10.1016/0922-4106(94)90057-4. [PMID: 7528679] - B Glaser, Y Nesher, S Barziliai. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
The Journal of reproductive medicine.
1994 Jun; 39(6):449-54. doi:
NULL. [PMID: 7932398] - T Svoboda, H Kotzmann, M Clodi, P Bernecker, G Geyer, A Luger. The non ergot D2-dopamine agonist CV 205-502 decreases growth hormone concentrations in acromegalic patients.
Endocrine research.
1994 Feb; 20(1):59-63. doi:
10.1080/07435809409035856. [PMID: 7909510] - J Trouillas, P Chevallier, B Claustrat, E Hooghe-Peters, C Dubray, B Rousset, C Girod. Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat.
Endocrinology.
1994 Jan; 134(1):401-10. doi:
10.1210/endo.134.1.7903933. [PMID: 7903933] - B Merola, F Sarnacchiaro, A Colao, C Di Somma, A Di Sarno, M L Landi, P Marzullo, N Panza, C Battista, G Lombardi. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
1994; 48(3-4):167-74. doi:
10.1016/0753-3322(94)90105-8. [PMID: 7993981] - T Nickelsen, E Jungmann, P Althoff, P M Schumm-Draeger, K H Usadel. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Arzneimittel-Forschung.
1993 Apr; 43(4):421-5. doi:
NULL. [PMID: 8098604] - Y Tomita, R W Engelman, I Bauer-Sardina, N K Day, R A Good. Improved enzyme immunosorbent assay for mouse prolactin using penicillinase as label.
Journal of immunological methods.
1992 Jul; 151(1-2):269-75. doi:
10.1016/0022-1759(92)90127-f. [PMID: 1352793] - W J Fassbender, H Stracke, G Bachmann, W Rau, K Federlin. Disappearance of a pituitary tumor after 15 months of treatment with CV 205-502, a new dopamine agonist.
The Clinical investigator.
1992 May; 70(5):444-6. doi:
10.1007/bf00235530. [PMID: 1350936] - T Brue, I Pellegrini, G Gunz, I Morange, D Dewailly, J Brownell, A Enjalbert, P Jaquet. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
The Journal of clinical endocrinology and metabolism.
1992 Mar; 74(3):577-84. doi:
10.1210/jcem.74.3.1346788. [PMID: 1346788] - D J Kwekkeboom, S W Lamberts. Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma.
Clinical endocrinology.
1992 Feb; 36(2):171-6. doi:
10.1111/j.1365-2265.1992.tb00953.x. [PMID: 1348979] - T Brue, I Pellegrini, A Priou, I Morange, P Jaquet. Prolactinomas and resistance to dopamine agonists.
Hormone research.
1992; 38(1-2):84-9. doi:
10.1159/000182496. [PMID: 1306523] - P S Barnett, E Palazidou, J P Miell, P B Coskeran, J Butler, J M Dawson, J Maccabe, A M McGregor. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
The Quarterly journal of medicine.
1991 Nov; 81(295):891-906. doi:
NULL. [PMID: 1687293] - T Svoboda, A Luger, E Knosp, G Geyer. [Treatment of prolactinoma with a new dopamine agonist].
Deutsche medizinische Wochenschrift (1946).
1991 Aug; 116(33):1224-7. doi:
10.1055/s-2008-1063739. [PMID: 1678695] - C Rasmussen, J Brownell, T Bergh. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502.
Acta endocrinologica.
1991 Aug; 125(2):170-6. doi:
10.1530/acta.0.1250170. [PMID: 1680264] - P F van der Heijden, W de Wit, J Brownell, J Schoemaker, R Rolland. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia.
European journal of obstetrics, gynecology, and reproductive biology.
1991 Jul; 40(2):111-8. doi:
10.1016/0028-2243(91)90101-p. [PMID: 1676973] - A J van der Lely, J Brownell, S W Lamberts. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
The Journal of clinical endocrinology and metabolism.
1991 May; 72(5):1136-41. doi:
10.1210/jcem-72-5-1136. [PMID: 1673685] - J P Miell, R Corder, F P Pralong, R C Gaillard. Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginine- and dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentrations in normal male volunteers.
The Journal of clinical endocrinology and metabolism.
1991 Mar; 72(3):675-81. doi:
10.1210/jcem-72-3-675. [PMID: 1671785] - L Duranteau, P Chanson, A Lavoinne, S Horlait, J Lubetzki, J M Kuhn. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
Clinical endocrinology.
1991 Jan; 34(1):25-9. doi:
10.1111/j.1365-2265.1991.tb01731.x. [PMID: 1672268] - P Birman, F Bai-Grenier, D Joubert. [EGF binding site number of rat anterior pituitary is increased by chronic administration with dopaminergic agonist, CV 205-502].
Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.
1991; 312(6):241-5. doi:
NULL. [PMID: 1675150] - J W van't Verlaat, R J Croughs, J Brownell. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
Clinical endocrinology.
1990 Nov; 33(5):619-24. doi:
10.1111/j.1365-2265.1990.tb03900.x. [PMID: 1979262] - O Serri, H Beauregard, J Lesage, L Pedneault, R Comtois, N Jilwan, M Somma, L Vachon, J Brownell. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas.
The Journal of clinical endocrinology and metabolism.
1990 Sep; 71(3):682-7. doi:
10.1210/jcem-71-3-682. [PMID: 2394774] - P S Barnett, J M Dawson, J Butler, P B Coskeran, J J Maccabe, A M McGregor. CV205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man.
Clinical endocrinology.
1990 Aug; 33(2):307-16. doi:
10.1111/j.1365-2265.1990.tb00495.x. [PMID: 1977537] - Y Khalfallah, B Claustrat, M Grochowicki, F Flocard, S Horlait, P Serusclat, G Sassolas. Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas.
The Journal of clinical endocrinology and metabolism.
1990 Aug; 71(2):354-9. doi:
10.1210/jcem-71-2-354. [PMID: 1974262] - M L Vance, M Lipper, A Klibanski, B M Biller, N A Samaan, M E Molitch. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.
Annals of internal medicine.
1990 May; 112(9):668-73. doi:
10.7326/0003-4819-112-9-668. [PMID: 1970714] - P Hedner, S Valdemarsson. Reduced size of a hormonally silent pituitary adenoma during treatment with CV 205-502, a new dopamine agonist mainly stimulating D2 receptors.
Neurosurgery.
1989 Dec; 25(6):948-50. doi:
10.1097/00006123-198912000-00015. [PMID: 2532309] - P Birman, P Touraine, F Bai-Grenier, C Dubray, T Kaabache, F Peillon, D Joubert. The stimulated C-kinase activity in estradiol-treated rat pituitaries is reduced by chronic treatment with the dopamine agonist CV 205-502.
Acta endocrinologica.
1989 Oct; 121(4):489-94. doi:
10.1530/acta.0.1210489. [PMID: 2572127] - P F van der Heijden, R E Lappöhn, R S Corbey, W B de Goeij, J Brownell, R Rolland. The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study.
Fertility and sterility.
1989 Oct; 52(4):574-9. doi:
10.1016/s0015-0282(16)60966-4. [PMID: 2806597] - C B Newman, A M Hurley, D L Kleinberg. Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.
Clinical endocrinology.
1989 Oct; 31(4):391-400. doi:
10.1111/j.1365-2265.1989.tb01263.x. [PMID: 2576397] - R C Gaillard, K Abeywickrama, J Brownell, A F Muller. Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test.
The Journal of clinical endocrinology and metabolism.
1989 Feb; 68(2):329-35. doi:
10.1210/jcem-68-2-329. [PMID: 2563733] - M L Vance, J R Cragun, C Reimnitz, R J Chang, E Rashef, R E Blackwell, M M Miller, M E Molitch. CV 205-502 treatment of hyperprolactinemia.
The Journal of clinical endocrinology and metabolism.
1989 Feb; 68(2):336-9. doi:
10.1210/jcem-68-2-336. [PMID: 2521863] - P F van der Heijden, R Rolland, C M Thomas, J Brownell. Endocrine effects of CV 205-502, a new dopamine agonist, in hyperprolactinemic women.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
1988 Sep; 2(3):233-48. doi:
10.3109/09513599809029348. [PMID: 3067546] - R C Gaillard, J Brownell. Hormonal effects of CV 205-502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties.
Life sciences.
1988; 43(17):1355-62. doi:
10.1016/0024-3205(88)90301-3. [PMID: 2903425] - C Rasmussen, T Bergh, L Wide, J Brownell. CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion.
Clinical endocrinology.
1987 Mar; 26(3):321-6. doi:
10.1111/j.1365-2265.1987.tb00789.x. [PMID: 3308186]